Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-28T03:16:29.664Z Has data issue: false hasContentIssue false
  • English
  • Français

Metabolomic profiles of 38 acylcarnitines in major depressive episodes before and after treatment

Published online by Cambridge University Press:  25 May 2023

Abd El Kader Ait Tayeb Open the ORCID record for Abd El Kader Ait Tayeb [Opens in a new window] ,
Romain Colle ,
Kenneth Chappell ,
Khalil El-Asmar ,
Cécile Acquaviva-Bourdain ,
Denis J. David ,
Séverine Trabado ,
Philippe Chanson ,
Bruno Feve  and
Laurent Becquemont
...Show all authors
Abd El Kader Ait Tayeb
Affiliation:
CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, Paris, F-94275, France
Romain Colle
Affiliation:
CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, Paris, F-94275, France
Kenneth Chappell
Affiliation:
CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France
Khalil El-Asmar
Affiliation:
CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon
Cécile Acquaviva-Bourdain
Affiliation:
Service de Biochimie et Biologie Moléculaire; Unité Médicale Pathologies Héréditaires du Métabolisme et du Globule Rouge; Centre de Biologie et Pathologie Est; CHU de Lyon; F-69500 Bron, France
Denis J. David
Affiliation:
CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France
Séverine Trabado
Affiliation:
INSERM UMR-S U1185, Physiologie et Physiopathologie Endocriniennes, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, F-94275, France
Philippe Chanson
Affiliation:
INSERM UMR-S U1185, Physiologie et Physiopathologie Endocriniennes, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, Hôpital de Bicêtre, Le Kremlin Bicêtre, F-94275, France
Bruno Feve
Affiliation:
Sorbonne Université-INSERM, Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire ICAN, Service d'Endocrinologie, CRMR PRISIS, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, F-75012, France
Laurent Becquemont
Affiliation:
CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France Centre de recherche clinique, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, Paris, F-94275, France
Céline Verstuyft
Affiliation:
CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, F-94275, France
Emmanuelle Corruble*
Affiliation:
CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, Paris, F-94275, France
*
Corresponding author: Emmanuelle Corruble; Email: emmanuelle.corruble@aphp.fr
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Major depression is associated with changes in plasma L-carnitine and acetyl-L-carnitine. But its association with acylcarnitines remains unclear. The aim of this study was to assess metabolomic profiles of 38 acylcarnitines in patients with major depression before and after treatment compared to healthy controls (HCs).

Methods

Metabolomic profiles of 38 plasma short-, medium-, and long-chain acylcarnitines were performed by liquid chromatography-mass spectrometry in 893 HCs from the VARIETE cohort and 460 depressed patients from the METADAP cohort before and after 6 months of antidepressant treatment.

Results

As compared to HCs, depressed patients had lower levels of medium- and long-chain acylcarnitines. After 6 months of treatment, increased levels of medium- and long-chain acyl-carnitines were observed that no longer differed from those of controls. Accordingly, several medium- and long-chain acylcarnitines were negatively correlated with depression severity.

Conclusions

These medium- and long-chain acylcarnitine dysregulations argue for mitochondrial dysfunction through fatty acid β-oxidation impairment during major depression.

Keywords

Acylcarnitinesantidepressantfatty acid oxidationmajor depressive disordermajor depressive episodemitochondria
Type
Original Article
Information
Psychological Medicine , Volume 54 , Issue 2 , January 2024 , pp. 289 - 298
Check for updates
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

These authors contributed equally to this work.

References

Ahmed, A. T., MahmoudianDehkordi, S., Bhattacharyya, S., Arnold, M., Liu, D., Neavin, D., … Kaddurah-Daouk, R. (2020). Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. Journal of Affective Disorders, 264, 90–97. https://doi.org/10.1016/j.jad.2019.11.122.CrossRefGoogle ScholarPubMed
Ait Tayeb, A. E. K., Colle, R., El-Asmar, K., Chappell, K., Acquaviva-Bourdain, C., David, D. J., … Corruble, E. (2023). Plasma acetyl-l-carnitine and l-carnitine in major depressive episodes: A case–control study before and after treatment. Psychological Medicine, 53(6), 2307–2316. https://doi.org/10.1017/S003329172100413X.CrossRefGoogle ScholarPubMed
Bartlett, K., & Eaton, S. (2004). Mitochondrial beta-oxidation. European Journal of Biochemistry, 271(3), 462–469. https://doi.org/10.1046/j.1432-1033.2003.03947.x.CrossRefGoogle ScholarPubMed
Cassol, E., Misra, V., Morgello, S., Kirk, G. D., Mehta, S. H., & Gabuzda, D. (2015). Altered monoamine and acylcarnitine metabolites in HIV-positive and HIV-negative subjects with depression. JAIDS Journal of Acquired Immune Deficiency Syndromes, 69(1), 18–28. https://doi.org/10.1097/QAI.0000000000000551.CrossRefGoogle ScholarPubMed
Chanson, P., Arnoux, A., Mavromati, M., Brailly-Tabard, S., Massart, C., & Young, J., … for the VARIETE Investigators. (2016). Reference values for IGF-I serum concentrations: Comparison of six immunoassays. The Journal of Clinical Endocrinology & Metabolism, 101(9), 3450–3458. https://doi.org/10.1210/jc.2016-1257.CrossRefGoogle ScholarPubMed
Chen, S., Wei, C., Gao, P., Kong, H., Jia, Z., Hu, C., … Xu, G. (2014). Effect of Allium macrostemon on a rat model of depression studied by using plasma lipid and acylcarnitine profiles from liquid chromatography/mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 89, 122–129. https://doi.org/10.1016/j.jpba.2013.10.045.CrossRefGoogle ScholarPubMed
Colle, R., Masson, P., Verstuyft, C., Fève, B., Werner, E., Boursier-Neyret, C., … Becquemont, L. (2020). Peripheral tryptophan, serotonin, kynurenine, and their metabolites in major depression: A case–control study. Psychiatry and Clinical Neurosciences, 74(2), 112–117. https://doi.org/10.1111/pcn.12944.CrossRefGoogle ScholarPubMed
Corruble, E., El Asmar, K., Trabado, S., Verstuyft, C., Falissard, B., Colle, R., … Becquemont, L. (2015). Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: Results of the METADAP cohort. World Psychiatry, 14(3), 366–367. https://doi.org/10.1002/wps.20260.CrossRefGoogle ScholarPubMed
Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., … Schiöth, H. B. (2022). Acylcarnitines: Nomenclature, biomarkers, therapeutic potential, drug targets, and clinical trials. Pharmacological Reviews, 74(3), 506–551. https://doi.org/10.1124/pharmrev.121.000408.CrossRefGoogle ScholarPubMed
Frye, R. E., Melnyk, S., & MacFabe, D. F. (2013). Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder. Translational Psychiatry, 3(1), e220–e220. https://doi.org/10.1038/tp.2012.143.CrossRefGoogle ScholarPubMed
Giménez-Palomo, A., Dodd, S., Anmella, G., Carvalho, A. F., Scaini, G., Quevedo, J., … Berk, M. (2021). The role of mitochondria in mood disorders: From physiology to pathophysiology and to treatment. Frontiers in Psychiatry, 12, 546801. https://doi.org/10.3389/fpsyt.2021.546801.CrossRefGoogle ScholarPubMed
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry, 23(1), 56–62. https://doi.org/10.1136/jnnp.23.1.56.CrossRefGoogle ScholarPubMed
Hamilton, P. J., Chen, E. Y., Tolstikov, V., Peña, C. J., Picone, J. A., Shah, P., … Nestler, E. J. (2020). Chronic stress and antidepressant treatment alter purine metabolism and beta oxidation within mouse brain and serum. Scientific Reports, 10(1), 18134. https://doi.org/10.1038/s41598-020-75114-5.CrossRefGoogle ScholarPubMed
Horgusluoglu, E., Neff, R., Song, W., Wang, M., Wang, Q., & Arnold, M., … the Alzheimer Disease Metabolomics Consortium. (2021). Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease. Alzheimer's & Dementia, 18(6), 1260–1278. https://doi.org/10.1002/alz.12468.CrossRefGoogle ScholarPubMed
Houten, S. M., & Wanders, R. J. A. (2010). A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. Journal of Inherited Metabolic Disease, 33(5), 469–477. https://doi.org/10.1007/s10545-010-9061-2.CrossRefGoogle Scholar
Jensen, N. J., Wodschow, H. Z., Nilsson, M., & Rungby, J. (2020). Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases. International Journal of Molecular Sciences, 21(22), 8767. https://doi.org/10.3390/ijms21228767.CrossRefGoogle ScholarPubMed
Kriisa, K., Leppik, L., Balõtšev, R., Ottas, A., Soomets, U., Koido, K., … Zilmer, M. (2017). Profiling of acylcarnitines in first episode psychosis before and after antipsychotic treatment. Journal of Proteome Research, 16(10), 3558–3566. https://doi.org/10.1021/acs.jproteome.7b00279.CrossRefGoogle ScholarPubMed
Kubota, Y., Goto, T., Hagiya, Y., Chohnan, S., & Toyoda, A. (2016). Decreased hepatic contents of coenzyme A molecular species in mice after subchronic mild social defeat stress. Stress (Amsterdam, Netherlands), 19(2), 192–197. https://doi.org/10.3109/10253890.2015.1137558.CrossRefGoogle ScholarPubMed
Lam, T. K. T., Schwartz, G. J., & Rossetti, L. (2005). Hypothalamic sensing of fatty acids. Nature Neuroscience, 8(5), 579–584. https://doi.org/10.1038/nn1456.CrossRefGoogle ScholarPubMed
Lehmann, R., Zhao, X., Weigert, C., Simon, P., Fehrenbach, E., Fritsche, J., … Niess, A. M. (2010). Medium chain acylcarnitines dominate the metabolite pattern in humans under moderate intensity exercise and support lipid oxidation. PLoS One, 5(7), e11519. https://doi.org/10.1371/journal.pone.0011519.CrossRefGoogle ScholarPubMed
Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443(7113), 787–795. https://doi.org/10.1038/nature05292.CrossRefGoogle ScholarPubMed
Liu, X., Zheng, P., Zhao, X., Zhang, Y., Hu, C., Li, J., … Xu, G. (2015). Discovery and validation of plasma biomarkers for major depressive disorder classification based on liquid chromatography–mass spectrometry. Journal of Proteome Research, 14(5), 2322–2330. https://doi.org/10.1021/acs.jproteome.5b00144.CrossRefGoogle ScholarPubMed
MahmoudianDehkordi, S., Ahmed, A. T.,Bhattacharyya, S., Han, X., Baillie, R. A., Arnold, M., … The Mood Disorders Precision Medicine Consortium (MDPMC). (2021). Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. Translational Psychiatry, 11(1), 153. https://doi.org/10.1038/s41398-020-01097-6.CrossRefGoogle ScholarPubMed
Malhi, G. S., & Mann, J. J. (2018). Depression. The Lancet, 392(10161), 2299–2312. https://doi.org/10.1016/S0140-6736(18)31948-2.CrossRefGoogle ScholarPubMed
Mallinckrodt, C. H., Sanger, T. M., Dubé, S., DeBrota, D. J., Molenberghs, G., Carroll, R. J., … Tollefson, G. D. (2003). Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biological Psychiatry, 53(8), 754–760. https://doi.org/10.1016/S0006-3223(02)01867-X.CrossRefGoogle ScholarPubMed
McGarry, J. D., Robles-Valdes, C., & Foster, D. W. (1975). Role of carnitine in hepatic ketogenesis. Proceedings of the National Academy of Sciences, 72(11), 4385–4388. https://doi.org/10.1073/pnas.72.11.4385.CrossRefGoogle ScholarPubMed
Merritt, J. L. II, Norris, M., & Kanungo, S. (2018). Fatty acid oxidation disorders. Annals of Translational Medicine, 6(24), 473–473. https://doi.org/10.21037/atm.2018.10.57.CrossRefGoogle ScholarPubMed
Mocking, R. J. T., Naviaux, J. C., Li, K., Wang, L., Monk, J. M., Bright, A. T., … Naviaux, R. K. (2021). Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence. Translational Psychiatry, 11(1), 37. https://doi.org/10.1038/s41398-020-01182-w.CrossRefGoogle ScholarPubMed
Moore, C. M., Christensen, J. D., Lafer, B., Fava, M., & Renshaw, P. F. (1997). Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: A phosporous-31 magnetic resonance spectroscopy study. American Journal of Psychiatry, 154(1), 116–118. https://doi.org/10.1176/ajp.154.1.116.Google ScholarPubMed
Mukerji, S. S., Misra, V., Lorenz, D. R., Chettimada, S., Keller, K., Letendre, S., … Gabuzda, D. (2021). Low neuroactive steroids identifies a biological subtype of depression in adults with human immunodeficiency virus on suppressive antiretroviral therapy. The Journal of Infectious Diseases, 223(9), 1601–1611. https://doi.org/10.1093/infdis/jiaa104.CrossRefGoogle ScholarPubMed
Nasca, C., Bigio, B., Lee, F. S., Young, S. P., Kautz, M. M., Albright, A., … Rasgon, N. (2018). Acetyl- l -carnitine deficiency in patients with major depressive disorder. Proceedings of the National Academy of Sciences, 115(34), 8627–8632. https://doi.org/10.1073/pnas.1801609115.CrossRefGoogle ScholarPubMed
Pu, J., Liu, Y., Zhang, H., Tian, L., Gui, S., Yu, Y., … Xie, P. (2021). An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder. Molecular Psychiatry, 26(8), 4265–4276. https://doi.org/10.1038/s41380-020-0645-4.CrossRefGoogle ScholarPubMed
Reuter, S. E., & Evans, A. M. (2012). Carnitine and acylcarnitines. Clinical Pharmacokinetics, 51(9), 553–572. https://doi.org/10.1007/BF03261931.CrossRefGoogle ScholarPubMed
Rotroff, D. M., Corum, D. G., Motsinger-Reif, A., Fiehn, O., Bottrel, N., Drevets, W. C., … Kaddurah-Daouk, R. (2016). Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: New mechanistic insights for rapid acting antidepressants. Translational Psychiatry, 6(9), e894–e894. https://doi.org/10.1038/tp.2016.145.CrossRefGoogle ScholarPubMed
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., … Schatzberg, A. F. (2006). Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology, 31(9), 1841–1853. https://doi.org/10.1038/sj.npp.1301131.CrossRefGoogle ScholarPubMed
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., … Keller, M. B. (2003). The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 54(5), 573–583. https://doi.org/10.1016/S0006-3223(02)01866-8.CrossRefGoogle ScholarPubMed
Saiki, S., Hatano, T., Fujimaki, M., Ishikawa, K.-I., Mori, A., Oji, Y., … Hattori, N. (2017). Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease. Scientific Reports, 7(1), 7328. https://doi.org/10.1038/s41598-017-06767-y.CrossRefGoogle ScholarPubMed
Souza, D. G., Almeida, R. F., Souza, D. O., & Zimmer, E. R. (2019). The astrocyte biochemistry. Seminars in Cell & Developmental Biology, 95, 142–150. https://doi.org/10.1016/j.semcdb.2019.04.002.CrossRefGoogle ScholarPubMed
Trabado, S., Al-Salameh, A., Croixmarie, V., Masson, P., Corruble, E., Fève, B., … Chanson, P. (2017). The human plasma-metabolome: Reference values in 800 French healthy volunteers; impact of cholesterol, gender and age. PLOS One, 12(3), e0173615. https://doi.org/10.1371/journal.pone.0173615.CrossRefGoogle ScholarPubMed
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., & Ritz, L., … STAR*D Study Team. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. American Journal of Psychiatry, 163(1), 28–40. https://doi.org/10.1176/appi.ajp.163.1.28.CrossRefGoogle ScholarPubMed
Warren, B. E., Lou, P.-H., Lucchinetti, E., Zhang, L., Clanachan, A. S., Affolter, A., … Lemieux, H. (2014). Early mitochondrial dysfunction in glycolytic muscle, but not oxidative muscle, of the fructose-fed insulin-resistant rat. American Journal of Physiology-Endocrinology and Metabolism, 306(6), E658–E667. https://doi.org/10.1152/ajpendo.00511.2013.CrossRefGoogle Scholar
White, C. J., Lee, J., Choi, J., Chu, T., Scafidi, S., & Wolfgang, M. J. (2020). Determining the bioenergetic capacity for fatty acid oxidation in the mammalian nervous system. Molecular and Cellular Biology, 40(10), e00037–20. https://doi.org/10.1128/MCB.00037-20.CrossRefGoogle ScholarPubMed
Xie, X., Shen, Q., Yu, C., Xiao, Q., Zhou, J., Xiong, Z., … Fu, Z. (2020). Depression-like behaviors are accompanied by disrupted mitochondrial energy metabolism in chronic corticosterone-induced mice. The Journal of Steroid Biochemistry and Molecular Biology, 200, 105607. https://doi.org/10.1016/j.jsbmb.2020.105607.CrossRefGoogle ScholarPubMed
Xue, S., Zhou, C., Xue, F., Liu, L., Cai, Y., Luo, J., … Peng, Z. (2020). The impact of repetitive transcranial magnetic stimulation and fluoxetine on the brain lipidome in a rat model of chronic unpredictable stress. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 102, 109946. https://doi.org/10.1016/j.pnpbp.2020.109946.CrossRefGoogle Scholar
Yang, X., Sun, L., Zhao, A., Hu, X., Qing, Y., Jiang, J., … Wan, C. (2017). Serum fatty acid patterns in patients with schizophrenia: A targeted metabonomics study. Translational Psychiatry, 7(7), e1176–e1176. https://doi.org/10.1038/tp.2017.152.CrossRefGoogle ScholarPubMed
Zacharias, H. U., Hertel, J., Johar, H., Pietzner, M., Lukaschek, K., Atasoy, S., … Ladwig, K.-H. (2021). A metabolome-wide association study in the general population reveals decreased levels of serum laurylcarnitine in people with depression. Molecular Psychiatry, 26, 7373–7383. https://doi.org/10.1038/s41380-021-01176-0.CrossRefGoogle ScholarPubMed
Supplementary material: File

Ait Tayeb et al. supplementary material

Tables S1-S8 and Figures S1-S3

Download Ait Tayeb et al. supplementary material(File)
File 441.4 KB